Cargando…
Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644028/ https://www.ncbi.nlm.nih.gov/pubmed/37969125 http://dx.doi.org/10.21037/tp-23-388 |
| _version_ | 1785147193240322048 |
|---|---|
| author | Carcaboso, Angel M. |
| author_facet | Carcaboso, Angel M. |
| author_sort | Carcaboso, Angel M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10644028 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106440282023-11-15 Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma Carcaboso, Angel M. Transl Pediatr Editorial Commentary AME Publishing Company 2023-10-10 2023-10-30 /pmc/articles/PMC10644028/ /pubmed/37969125 http://dx.doi.org/10.21037/tp-23-388 Text en 2023 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Carcaboso, Angel M. Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title | Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title_full | Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title_fullStr | Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title_full_unstemmed | Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title_short | Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma |
| title_sort | results from the children’s oncology group phase iii trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic ewing sarcoma |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644028/ https://www.ncbi.nlm.nih.gov/pubmed/37969125 http://dx.doi.org/10.21037/tp-23-388 |
| work_keys_str_mv | AT carcabosoangelm resultsfromthechildrensoncologygroupphaseiiitrialofamonoclonalantibodyagainsttheinsulinlikegrowthfactor1receptorinpatientswithnewlydiagnosedmetastaticewingsarcoma |